NYHA FC and Finerenone Response: Clinical Trial Insights
Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves patient outcomes in HFmrEF/HFpEF, regardless of baseline NYHA class.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!